Vident Advisory LLC Invests $744,000 in Bath & Body Works, Inc. $BBWI

Key Points

• Vident Advisory LLC acquired 24,537 shares of Bath & Body Works, valued at approximately $744,000, as part of their new position in the company.
• Bath & Body Works reported $0.37 earnings per share, meeting consensus estimates, while the revenue for the quarter was slightly down by 0.8% compared to the previous year.
• The company declared a quarterly dividend of $0.20, representing a yield of 2.5%, with the ex-dividend date set for August 22nd.

Vident Advisory LLC acquired a new position in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 24,537 shares of the company's stock, valued at approximately $744,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SVB Wealth LLC bought a new stake in Bath & Body Works during the first quarter worth about $35,000. Golden State Wealth Management LLC lifted its holdings in shares of Bath & Body Works by 94.7% during the first quarter. Golden State Wealth Management LLC now owns 1,320 shares of the company's stock valued at $40,000 after purchasing an additional 642 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Bath & Body Works by 65.9% during the first quarter. UMB Bank n.a. now owns 1,501 shares of the company's stock valued at $46,000 after purchasing an additional 596 shares during the last quarter. Ancora Advisors LLC bought a new stake in shares of Bath & Body Works in the 4th quarter worth approximately $67,000. Finally, GKV Capital Management Co. Inc. purchased a new stake in shares of Bath & Body Works in the 1st quarter worth approximately $69,000. Hedge funds and other institutional investors own 95.14% of the company's stock.

Bath & Body Works Stock Down 0.2%

NYSE:BBWI traded down $0.07 on Wednesday, hitting $28.15. The stock had a trading volume of 5,567,215 shares, compared to its average volume of 6,464,255. The business's 50-day simple moving average is $30.53 and its two-hundred day simple moving average is $30.35. The stock has a market cap of $5.81 billion, a price-to-earnings ratio of 8.35, a price-to-earnings-growth ratio of 0.97 and a beta of 1.49. Bath & Body Works, Inc. has a 52-week low of $24.94 and a 52-week high of $41.87.

Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its earnings results on Thursday, August 28th. The company reported $0.37 EPS for the quarter, meeting analysts' consensus estimates of $0.37. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The business had revenue of $1.55 billion during the quarter, compared to analysts' expectations of $1.55 billion. During the same period in the prior year, the company earned $0.37 earnings per share. The firm's revenue was down .8% on a year-over-year basis. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. As a group, equities research analysts anticipate that Bath & Body Works, Inc. will post 3.3 EPS for the current year.

Bath & Body Works Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 5th. Stockholders of record on Friday, August 22nd were given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, August 22nd. Bath & Body Works's payout ratio is presently 23.74%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Telsey Advisory Group reissued an "outperform" rating and issued a $38.00 target price on shares of Bath & Body Works in a research note on Thursday, August 28th. Wall Street Zen downgraded shares of Bath & Body Works from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. The Goldman Sachs Group decreased their target price on shares of Bath & Body Works from $44.00 to $43.00 and set a "buy" rating for the company in a report on Friday, May 30th. UBS Group cut their price target on shares of Bath & Body Works from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, August 29th. Finally, Barclays boosted their price objective on shares of Bath & Body Works from $30.00 to $32.00 and gave the stock an "equal weight" rating in a report on Friday, August 29th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.62.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.